Physician profile
Han Lam
NPI 1215432646
$6,275.17
in general payments reported to CMS, 2019-2025
45 companies · $3,176 in 2025
The $3,176 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $166 · 2022: $321 · 2023: $408 · 2024: $2,205 · 2025: $3,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,756 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,755.61 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $701.92 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $689.65 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.31 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $477.31 | 2022-2025 | Tepezza, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $306.84 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $301.74 | 2023-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Mannkind Corporation | $290.92 | 2023-2025 | Afrezza |
| Abbott Laboratories | $290.36 | 2024-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $192.23 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $188.62 | 2023-2025 | |
| Ascendis Pharma Endocrinology INC | $185.60 | 2025 | Yorvipath |
| Corcept Therapeutics | $184.15 | 2023-2025 | Korlym |
| Sequel Med Tech, LLC | $168.73 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $157.82 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $124.99 | 2020 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $122.89 | 2023-2025 | Tymlos |
| Insulet Corporation | $118.17 | 2024-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $116.62 | 2024-2025 | |
| Horizon Therapeutics Plc | $107.10 | 2022 | |
| Recordati_rare_diseases_inc. | $105.49 | 2023-2025 | Isturisa, Signifor Lar |
| Amphastar Pharmaceuticals, INC. | $100.97 | 2024-2025 | |
| Ascensia Diabetes Care US INC. | $94.34 | 2024-2025 | |
| Alvogen INC | $79.49 | 2023-2025 | Teriparatide |
| Madrigal Pharmaceuticals | $71.28 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $56.94 | 2024-2025 | Unithroid |
| Medtronic, INC. | $50.85 | 2024 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $46.33 | 2024-2025 | Strensiq |
| Genzyme Corporation | $41.00 | 2020 | |
| Tandem Diabetes Care, INC. | $40.38 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $37.17 | 2023 | Tirosint, Licart |
| Tolmar, INC. | $28.11 | 2024 | |
| Acella Pharmaceuticals, LLC | $27.93 | 2024-2025 | NP Thyroid 60 |
| Averitas Pharma INC. | $27.53 | 2025 | Qutenza |
| Halozyme INC | $24.28 | 2023 | |
| Pfizer INC. | $18.79 | 2024 | |
| Chiesi USA, INC. | $18.32 | 2025 | Mycapssa |
| Lifescan, INC. | $17.39 | 2023 | |
| Verity Pharmaceuticals INC. | $17.34 | 2025 | Tlando |
| Amryt Pharma Holdings Ltd | $17.25 | 2023 | Mycapssa |
| Azurity Pharmaceuticals, INC. | $16.56 | 2025 | Azmiro |
| Cequr Corporation | $15.79 | 2024 | Cequr Simplicity |
| Astellas Pharma US INC | $14.75 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $14.17 | 2025 | Shingrix |
| Esperion Therapeutics, INC. | $13.58 | 2024 | Nexletol |
| Beta Bionics, INC. | $9.17 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Han Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.